We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GI
51
DELISTED
EndoChoice Holdings, Inc.
GI
$9.42M 0.69%
+575,920
New +$9.57M
DHR icon
52
Danaher
DHR
$144B
$9.03M 0.66%
156,966
– –
GWPH
53
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9M 0.66%
73,250
+3,250
+5% +$369K
INSM icon
54
Insmed
INSM
$28.6B
$8.91M 0.65%
365,000
– –
PRGO icon
55
Perrigo
PRGO
$1.78B
$8.69M 0.63%
47,000
– –
MCRB icon
56
Seres Therapeutics
MCRB
$48.4M
$8.6M 0.63%
+10,361
New +$9.04M
ALPN
57
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.55M 0.62%
+141,090
New +$8.4M
ADXS
58
DELISTED
Advaxis Inc
ADXS
$8.49M 0.62%
27,833
-4,834
-15% -$1.53M
ELV icon
59
Elevance Health
ELV
$85.5B
$8.45M 0.62%
+51,500
New +$8.23M
VRTX icon
60
Vertex Pharmaceuticals
VRTX
$126B
$8.4M 0.61%
68,000
– –
ZSPH
61
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$8.33M 0.61%
159,000
+1,000
+0.6% +$49.2K
NVAX icon
62
Novavax
NVAX
$1.31B
$7.96M 0.58%
35,750
-750
-2% -$132K
RLYP
63
DELISTED
RELYPSA INC COM
RLYP
$7.95M 0.58%
240,100
+35,100
+17% +$1.21M
LKFT
64
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$7.85M 0.57%
+152,500
New +$8.09M
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.84M 0.57%
32,500
-3,500
-10% -$932K
OREX
66
DELISTED
Orexigen Therapeutics, Inc.
OREX
$7.67M 0.56%
155,000
– –
BLUE
67
DELISTED
bluebird bio
BLUE
$7.58M 0.55%
3,474
+1,544
+80% +$3.15M
ATYR
68
aTyr Pharma
ATYR
$50.1M
$7.57M 0.55%
+29,178
New +$9.06M
OTIC
69
DELISTED
Otonomy, Inc.
OTIC
$7.38M 0.54%
+320,800
New +$9M
EPZM
70
DELISTED
Epizyme, Inc
EPZM
$7.36M 0.54%
306,500
– –
KITE
71
DELISTED
Kite Pharma, Inc.
KITE
$7.19M 0.53%
118,000
+46,526
+65% +$2.65M
IDXX icon
72
Idexx Laboratories
IDXX
$46.2B
$7.12M 0.52%
+111,000
New +$7.68M
WX
73
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$7.1M 0.52%
168,000
– –
CNXR
74
DELISTED
Connecture, Inc.
CNXR
$6.6M 0.48%
625,000
+25,000
+4% +$276K
NVDQ
75
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.54M 0.48%
540,000
+65,000
+14% +$776K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.